Ensatinib hydrochloride, a new drug of Beida pharmaceutical, was included in the priority review procedure by the State Food and Drug Administration
-
Last Update: 2019-02-25
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Beida pharmaceutical has just released a notice that its new drug, ensatinib hydrochloride, was included in the publicity list of the proposed priority review varieties by the drug review center of the National Drug Administration (nmpa) on February 15, 2019 Now the publicity period has expired, and it will officially enter the priority review process Ensatinib hydrochloride is a new type of highly effective and selective new generation of anaplastic lymphoma kinase (ALK) ALK inhibitor In addition to the clinical trial for which production basis is declared, Beida pharmaceutical industry is also promoting the international multicenter phase III clinical trial for patients with ALK positive or metastatic non-small cell lung cancer (NSCLC), which has been conducted at the end of 2018 Patients were enrolled before The following is the original announcement:
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
